Compare Liquidia Corporation Common Stock (LQDA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liquidia Corporation Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Liquidia Corporation Common Stock trades at $33.66 (market cap $2.40B), while State Street SPDR S&P Biotech ETF trades at $147.06 (market cap $10.27B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 4.3× Liquidia Corporation Common Stock's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 39 Days on average.
| LQDA | XBI | |
|---|---|---|
Market Cap | $2.40B | $10.27B |
Volume | 2,857,547 | 9,751,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $91.03 | $169.55 |
52-Week Low | $22.02 | $107.32 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $2.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $146.8, down 3.04% today, with a bearish technical signal driven by selling pressure in moving averages. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than diversified healthcare funds.
Outlook remains mixed with neutral analyst consensus but positive sector catalysts. Opportunities include biotech innovation and M&A potential, while risks involve high volatility, regulatory uncertainty, and expense ratios above broader healthcare ETFs. Investors should weigh targeted biotech exposure against sector-wide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Liquidia Corporation Common Stock
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
